Melan-A Antibody (0.N.396): sc-71567
- Melan-A Antibody (0.N.396) is a mouse monoclonal IgG2b provided at 200 µg/ml
- raised against recombinant Melan-A of human origin
- recommended for detection of Melan-A of human origin by WB, IP, IF and IHC(P)
- See Melan-A (A103): sc-20032 for Melan-A antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Melan-A Antibody (0.N.396). This work is in progress.
QUICK LINKS
SEE ALSO...
Melan-A Antibody (0.N.396) is a mouse monoclonal IgG2b antibody that detects Melan-A in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Melan-A, also known as MART-1, is a crucial melanocyte differentiation antigen predominantly expressed in melanomas, melanocyte cell lines, and retinal tissues. Melan-A (0.N.396) antibody serves as a valuable tool for studying a target recognized by cytotoxic T lymphocytes, which are essential for the immune response against melanoma. The Melan-A peptide is recognized by a majority of HLA-A2-restricted tumor-infiltrating lymphocytes in melanoma patients, highlighting its potential as a candidate for antigen-specific immunotherapy. The ability to generate anti-melanoma cytotoxic T lymphocytes using Melan-A peptides underscores the importance of Melan-A in developing targeted cancer therapies. Anti-Melan-A antibody (0.N.396) enables researchers to effectively study the expression and function of this vital protein, contributing to advancements in melanoma treatment and immunotherapy strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Melan-A Antibody (0.N.396) References:
- High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. | Pittet, MJ., et al. 1999. J Exp Med. 190: 705-15. PMID: 10477554
- A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. | Bergman, R., et al. 2000. J Am Acad Dermatol. 42: 496-500. PMID: 10688724
- MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression. | Strohal, R., et al. 2001. Melanoma Res. 11: 543-8. PMID: 11595894
- Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. | Mandruzzato, S., et al. 2002. J Immunol. 169: 4017-24. PMID: 12244204
- Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. | Weber, J., et al. 2008. J Immunother. 31: 215-23. PMID: 18481391
- Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. | Khammari, A., et al. 2009. J Invest Dermatol. 129: 2835-42. PMID: 19554023
- Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. | Robson, NC., et al. 2010. Blood. 116: 218-25. PMID: 20430956
- TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. | Borbulevych, OY., et al. 2011. J Immunol. 187: 2453-63. PMID: 21795600
- Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. | Lai, J., et al. 2018. Biomaterials. 178: 158-169. PMID: 29933102
- Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. | D'Souza, S., et al. 1998. Int J Cancer. 78: 699-706. PMID: 9833762
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Melan-A Antibody (0.N.396) | sc-71567 | 200 µg/ml | $316.00 |